Analysis
Triveni Bio raised $65 million in a round co-led by Ascenta Capital and Janus Henderson Investors to develop antibody-based therapeutics for immunological diseases. The capital will fund the company's pipeline as it advances candidates toward and through clinical development.
The round is notable less for its size than for what it signals about biotech sentiment. After a brutal multi-year funding winter, the participation of crossover investors like Janus Henderson points to renewed appetite for clinical-stage life sciences -- a sector that had been overshadowed by the gravitational pull of AI.
“The round is notable less for its size than for what it signals about biotech sentiment.”
Immunology continues to attract capital because the biology is increasingly well understood, the addressable markets are large, and clinical endpoints are comparatively clear. For a venture landscape dominated by AI headlines, Triveni is a reminder that healthcare and biotech remain a major, distinct pillar of innovation funding.
